【NSO“新冠免疫与抗体”专题】朱凤才等：癌症患者接种新冠疫苗的挑战

Challenges of COVID-19 vaccination in patients with cancer

Siyue Jia, Wenbo Zhu, Hudachuan Jiang & Fengcai Zhu

https://doi.org/10.1360/nso/20220004

文章亮点内容：

本综述总结了全球在癌症患者中开展的新冠疫苗临床研究结果和有关部门发布的相关指南，提供了有限但至关重要的癌症患者接种新冠疫苗的安全性和免疫原性数据，为在癌症患者中推广新冠疫苗接种提供了科学证据。同时，也讨论了在癌症患者中推进精准免疫策略所面临的挑战。这是科学界乃至全社会关注的热点话题。

论文摘要：

Patients with cancer are atincreased risk of SARA-CoV-2infection or developing severe COVID-19 cases due to the malignancy orimmunosuppressive therapy, but they are generally excluded from the targetpopulation for COVID-19vaccination. In general, inactivated vaccines are safe and immunogenic for patients with cancer, butlive attenuated vaccines are not recommended.The study suggested thatthe safety of the mRNA COVID-19 vaccine in cancer patients is similar to thatin healthy people, but the immunogenicity is slightly weaker, and a booster dosemay be needed. This paper aims to summarize the results of COVID-19 vaccineclinical studies conducted in cancer patients worldwide and the relevantguidelines released by authorities, so as to provide evidence for promotingCOVID-19 vaccination for cancer patients.

癌症患者因恶性肿瘤或免疫抑制治疗而导致感染新冠或发展为重症新冠病例的风险增加，但他们通常被排除在新冠疫苗接种的目标人群之外。一般来说，灭活疫苗对于癌症患者是安全且具有免疫原性的，但不推荐他们接种减毒活疫苗。研究表明，mRNA新冠疫苗在癌症患者中的安全性与在健康人中的安全性相似，但免疫原性稍弱，可能需要加强免疫。本文旨在总结国内外在癌症患者中开展的新冠疫苗临床研究的结果和权威机构发布的相关指南，为促进癌症患者接种新冠疫苗提供依据。

转自：“中国科学杂志社”微信公众号

如有侵权，请联系本站删除！